Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001415889-25-016726
Filing Date
2025-06-11
Accepted
2025-06-11 17:40:49
Documents
2
Period of Report
2025-06-09

Document Format Files

Seq Description Document Type Size
1 form3-06112025_090646.html 3  
1 form3-06112025_090646.xml 3 1699
2 ex24-06112025_090647.htm EX-24 6146
  Complete submission text file 0001415889-25-016726.txt   9283
Mailing Address C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108
Business Address
Meltz Mark A (Reporting) CIK: 0001771329 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40502 | Film No.: 251041049

Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Issuer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)